Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: FDA Oversight hearing

Executive Summary

FDA Oversight hearing: Witnesses scheduled to testify June 19 before the House Commerce/Oversight Subcommittee include Tufts' Louis Lasagna, MD, Wilkes University's Arthur Kibbe, PhD, National Coalition for Cancer Survivorship Executive Director Ellen Stovall and Genzyme VP-Clinical, Medical & Regulatory Affairs Richard Moscicki, MD. Lasagna was previously scheduled to testify before the subcommittee May 25 but could not appear due to travel difficulties. Kibbe, while an official with the American Pharmaceutical Association, was one of three consultants who authored a report on the generic drug review process in 1991...
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026375

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel